The first participant of the SCA7 study reported yesterday at our Radboudumc Expertise Center for Rare and Hereditary Movement Disorders.
With this, we have officially started the research into the natural course and possible biomarkers in this disease! This is an important step towards the ultimate long-term goal: slow down, stop or prevent the disease!
During the research, a collaboration between LUMC and Radboudumc, we will keep you informed of the latest developments and if you have any questions about this component, please feel free to contact us at sca7-studie.neuro@radboudumc.nl.

SCA7 research started